Myris Therapeutics

Coming – May 7

Game-changing Precision Medicine Platform To Treat Virtually Any Cancer

Date and Time

May 7

–

12:00 PM ET / 9:00 AM PT

Details will be provided upon RSVP approval

About this Event

Myris Therapeutics is a biotech innovator that’s revolutionizing the delivery of small molecule cancer therapies with its HiDAR Precision Medicine Platform.

HiDAR is made possible by an innovative polymerization technology that enables drug loading 10-50x higher than any approved ADC. Traditional ADCs carry between 2 and 8 drug payloads per antibody. HiDARs, however, can carry anywhere from 50 to more than 300 drug payloads per antibody, allowing it to transport multiple different small molecules, creating combination therapies in a single dose. Not only does this improve efficacy, but their stable linker technology minimizes systemic toxicity, opening the door to more durable responses.

Myris’ lead program is targeting Colorectal Cancer, a disease that impacts 150,000 people per year in the U.S., the #1 cause of cancer related deaths in adults under 50. Myris will have two development candidates ready for IND enabling CMC and pharmacology studies by early 2027. The company has a scalable manufacturing approach, a clear development roadmap, and the ability to treat most solid tumor cancers including colon, pancreatic, breast and lung.

Join our online event with Myris Therapeutics CEO, Laura Benjamin, to hear how Myris is positioned at the intersection of scientific innovation and significant market demand.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.